Syndax Pharmaceuticals Inc (SNDX)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Total revenues | 37,958 | - | 12,500 | |
| Research and development | 62,227 | - | 70,971 | |
| Selling, general and administrative | 43,805 | - | 31,106 | |
| Cost of product sales | 1,279 | - | - | |
| Total operating expenses | 107,311 | - | 102,077 | |
| Loss from operations | -69,353 | - | -89,577 | |
| Other income (expense) | - | - | 32 | |
| Royalty interest expense | 7,854 | - | - | |
| Other expense | 586 | - | - | |
| Interest income | 5,950 | - | 5,442 | |
| Other interest expense | 4 | - | 23 | |
| Total other income, net | -2,494 | - | 5,451 | |
| Net loss | -71,847 | - | -82,938 | |
| Unrealized gain on marketable securities | - | - | 1,188 | |
| Comprehensive income (loss), net of tax, attributable to parent | - | - | -82,938 | |
| Earnings per share, basic, total | -0.83 | -0.98 | -0.98 | |
| Earnings per share, diluted, total | -0.83 | -0.98 | -0.98 | |
| Weighted average number of shares outstanding, basic, total | 86,337,237 | 86,171,889 | 85,433,569 | |
| Weighted-average number of common shares used to compute net loss per share attributable to common stockholdersdiluted | 86,337,237 | 86,171,889 | 85,433,569 | |